Clinical Study Of Atorvastatin And Nicorandil In The Treatment Of Coronary Artery Slow Blood Flow

Objective: To investigate the clinical efficacy of Atorvastatin Combined with nicorandil in the treatment and prevention of coronary slow flow and adverse reaction, provide more experience for clinical treatment.Methods: randomly selected from 2012 January to 2014 January 9 in the Department of Cardiology of Affiliated Hospital of Qingdao University Medical College diagnosed by coronary angiography in patients with slow blood flow was observed in 60 patients, and randomly divided into 3groups, each group of 20 people, were given different treatment, onegroup received atorvastatin therapy, another group was given Nicole E1,the last group of the Atorvastatin Combined with nicorandil combined treatment. The anterior descending coronary artery, collecting the patient before the treatment of the circumflex artery and angiography, right coronary artery blood frames, made in the patient informed and consent,from the value of venous blood plasma hs-CRP and ET-1, and 6 minuteswalk test results. The subjects were prescribed medication according to the experimental design, 3 months of treatment, this process was notfollowed up regularly, and the patients in trial a week to do a routine ECG examination, 3 months after the end, numerical check again the plasma levels of hs-CRP and ET-1, and 6 minutes walk test results and recordstatistics, 3 within a month the patients with chest pain, chest tightness,the number of attacks and other symptoms, and adverse reaction. All the data were analyzed by using Spss16.0statistical software.Results: 3 groups of patients before treatment and condition based onthe comparison of coronary flow imaging frames were not statistically significant(p less than 0.05), 3 groups of patients after treatment andbefore treatment, plasma hs-CRP, ET-1, a value of 6 minute walk test,results were improved(p less than 0.05), in the view of hs-CRP: after the treatment of numerical combination group than the Atorvastatin group,atorvastatin group Binikedier numerical atorvastatin group is low; in the view of ET-1: low numerical combination group Binikedier after treatmentgroup, nicorandil group simvastatin group value lower than a support; inthe 6 minute walk test: treatment after the numerical Binikediercombination group were higher than the values, nicorandil groupatorvastatin group was high. In comparison to the degree of improvement of the clinical symptoms, combined drug group than atorvastatin groupand nicorandil group improved significantly, the difference was statistically significant(P < 0.05), nicorandil group than atorvastatingroup treatment effect(p less than 0.05). Adverse reactions of 3 groups had no significant difference.Conclusion: atorvastatin and nicorandil alone can effectively improve theslow flow condition, the effect of nicorandil was better than atorvastatin,combined with atorvastatin and nicorandil in patients without increasing adverse reactions at the same time, can be more effective in the treatment of slow flow. Is a worthy of clinical reference treatment method,in view of the small sample in the test, the conclusion has some limitations, this topic research expected later will have larger samples to obtain more accurate conclusions.